텍사스의 담도계 암 임상 시험
담도계 암 관련 연구 23개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.
텍사스의 도시
공식 연구 텍스트(영어)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- University of Texas Southwestern Medical Center (Site 104), Dallas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Houston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06428409Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
피험자 모집 중2상
18세 ~ 130세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT06293898CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06548412AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Dallas
- Avenzo Therapeutics Recruiting Site, Houston
- Avenzo Therapeutics Recruiting Site, San Antonio
피험자 모집 중1/2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07038343Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT06084481A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- MD Anderson, Houston
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Dallas
- Research Site, Fort Worth
- Research Site, Houston
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
피험자 모집 중2상
8세 이상 · 모든 성별 · 2026. 7. 27. 업데이트됨 · NCT05503797A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT07458347A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1상
16세 이상 · 모든 성별 · 2026. 6. 2. 업데이트됨 · NCT07197554Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT06239194Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 2. 업데이트됨 · NCT05733598This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- NEXT Oncology, Austin, TX 78758
- NEXT Oncology, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 2. 업데이트됨 · NCT06451497Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 27. 업데이트됨 · NCT06789848A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 12. 11. 업데이트됨 · NCT06943521ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.